GamaMabs Pharma starts phase Ia/Ib study of first-in-class monoclonal antibody GM102 in advanced gynecological cancer

GamaMabs Pharma starts phase Ia/Ib study of first-in-class monoclonal antibody GM102 in advanced gynecological cancer

  Toulouse and Paris, France, July 26, 2016 – GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies for the…